January 24, 2022
JCR Pharmaceuticals said on January 21 that the European Commission has granted orphan drug designation to JR-441, an investigational agent for mucopolysaccharidosis type III A (MPS IIIA). JR-441 is a blood-brain barrier (BBB)-penetrating form of recombinant heparan N-sulfatase developed based...read more